218 related articles for article (PubMed ID: 30687970)
1. Efficacy and safety of a new intravenous immunoglobulin (Panzyga
Arbach O; Taumberger AB; Wietek S; Cervinek L; Salama A
Transfus Med; 2019 Feb; 29(1):48-54. PubMed ID: 30687970
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.
Robak T; Salama A; Kovaleva L; Vyhovska Y; Davies SV; Mazzucconi MG; Zenker O; Kiessling P;
Hematology; 2009 Aug; 14(4):227-36. PubMed ID: 19635187
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP.
Colovic M; Dimitrijevic M; Sonnenburg C; Suvajdzic N; Donfrid M; Bogdanovic A
Hematol J; 2003; 4(5):358-62. PubMed ID: 14502262
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
Hong J; Bang SM; Mun YC; Yhim HY; Lee J; Lim HS; Oh D;
J Korean Med Sci; 2018 May; 33(19):e142. PubMed ID: 29736158
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
10. Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.
Yildiz I; Ozdemir N; Celkan T; Soylu S; Karaman S; Canbolat A; Dogru O; Erginoz E; Apak H
Pediatr Hematol Oncol; 2015; 32(6):406-14. PubMed ID: 26154620
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials.
Qin YH; Zhou TB; Su LN; Lei FY; Zhao YJ; Huang WF
Blood Coagul Fibrinolysis; 2010 Dec; 21(8):713-21. PubMed ID: 20962624
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.
Heitink-Pollé KMJ; Uiterwaal CSPM; Porcelijn L; Tamminga RYJ; Smiers FJ; van Woerden NL; Wesseling J; Vidarsson G; Laarhoven AG; de Haas M; Bruin MCA;
Blood; 2018 Aug; 132(9):883-891. PubMed ID: 29945954
[TBL] [Abstract][Full Text] [Related]
14. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial.
Benesch M; Kerbl R; Lackner H; Berghold A; Schwinger W; Triebl-Roth K; Urban C
J Pediatr Hematol Oncol; 2003 Oct; 25(10):797-800. PubMed ID: 14528103
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T
J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravenous immunoglobulin (Flebogamma
Apte S; Navarro-Puerto J; Damodar S; Ramanan V; John J; Kato G; Ross C; Shah C; Torres M; Fu C'; Rucker K; Pinciaro P; Barrera G; Aragonés ME; Ayguasanosa J
Immunotherapy; 2019 Feb; 11(2):81-89. PubMed ID: 30499734
[TBL] [Abstract][Full Text] [Related]
17. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience.
Alioglu B; Ercan S; Tapci AE; Zengin T; Yazarli E; Dallar Y
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):505-9. PubMed ID: 23470649
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of intravenous immunoglobulin use in immune thrombocytopenia (ITP): A Canadian centre deep dive audit.
Liu J; Pavenski K; Sholzberg M
Transfus Apher Sci; 2019 Aug; 58(4):491-494. PubMed ID: 31105060
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur.
Ou CY; Hsieh KS; Chiou YH; Chang YH; Ger LP
Acta Paediatr Taiwan; 2006; 47(5):226-31. PubMed ID: 17352309
[TBL] [Abstract][Full Text] [Related]
20. The experience of Flebogammadif® in primary immune thrombocytopenia.
Julia A
Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):12-5. PubMed ID: 21466547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
